Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting androgen receptor with non-steroidal next-generation radiopharmaceuticals

Award Number: K99CA312787
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 08/01/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2028

Group Awards By:

View Award Description

Targeting androgen receptor with non-steroidal next-generation radiopharmaceuticals - PROJECT SUMMARY There are currently 3.4 million men living with prostate cancer in the United States. Androgen receptor (AR) is a ligand activated transcription factor and a key driver in prostate cancer that sustains and drives cancer cell proliferation. Consequently, AR-targeted therapies (androgen deprivation therapy and AR signaling inhibitors), are central to current treatment strategies. Continuous expression of AR remains throughout the disease while resistance to AR directed therapies occur broadly. This underscores the urgent need for novel therapeutic approaches that can effectively target AR in lesions resistant to current treatment options. Radiotheranostics offers a promising strategy by combining disease target validation and targeted delivery of cytotoxic agents using biologically active diagnostic and therapeutic radiopharmaceuticals. We are proposing to develop a radiotheranostic platform for the disease monitoring and treatment of androgen receptor driven tumor lesions. As part of our innovative technology we are harnessing our non-steroidal androgen receptor agonists for DNA targeting Auger electron therapy. The in vivo evaluation of the platform will be conducted using prostate cancer mouse models, specifically androgen-dependent (LNCaP) and androgen-independent (LNCaP-abl) human xenograft models established in athymic male nude mice. The use of these models is essential to assess targetspecific uptake and clearance of the proposed radiotheranostic agents, as well as to evaluate their therapeutic efficacy in a biologically relevant system. The complex interplay of endogenous androgen production in the adrenal glands and testis in the context of studying the target interaction of our radioligands in different cancer models cannot be explored substantively in any existing in vitro models. The animal models included in the proposed research provide a necessary environment to study these interactions. The proposed work will be conducted by the PI, Vilma Jallinoja at the Department of Radiology at Memorial Sloan Kettering Cancer Center. Her research will be supported by her collaborators, Dr. Kishore Pillarsetty, Dr. John Humm, Dr. Elizabeth Wasmuth, Dr. Michael Morris, Dr. Audrey Mauguen and Dr. Yu Chen. Together, they will provide critical scientific and professional guidance to help Dr. Jallinoja achieve her overarching goal of becoming an independent research group leader, specializing in the investigation of the androgen receptor across various cancers using nuclear medicine techniques.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $153,330 )
2026	2026	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	000	1	7/29/2026	NEW	$153,330
														Subtotal = $153,330

Grand Total All Awards = $153,330

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting androgen receptor with non-steroidal next-generation radiopharmaceuticals

Award Number: K99CA312787

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 08/01/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer